国产bbaaaaa片,成年美女黄网站色视频免费,成年黄大片,а天堂中文最新一区二区三区,成人精品视频一区二区三区尤物

首頁> 美國衛(wèi)生研究院文獻(xiàn)>GMS Infectious Diseases >Evaluation of the SARS-CoV-2-IgG response in outpatients by five commercial immunoassays
【2h】

Evaluation of the SARS-CoV-2-IgG response in outpatients by five commercial immunoassays

機(jī)譯：用五種商業(yè)免疫測定的門診患者SARS-COV-2-IgG反應(yīng)的評價

代理獲取
本網(wǎng)站僅為用戶提供外文OA文獻(xiàn)查詢和代理獲取服務(wù)，本網(wǎng)站沒有原文。下單后我們將采用程序或人工為您竭誠獲取高質(zhì)量的原文，但由于OA文獻(xiàn)來源多樣且變更頻繁，仍可能出現(xiàn)獲取不到、文獻(xiàn)不完整或與標(biāo)題不符等情況，如果獲取不到我們將提供退款服務(wù)。請知悉。
  • 摘要
  • 著錄項(xiàng)
  • 相似文獻(xiàn)
  • 相關(guān)主題

摘要

Commercially available immunoassays have been developed for sensitive and specific detection of antibodies against SARS-CoV-2. While high sensitivity has been reported in hospitalized COVID-19 patients, little is known about the performance of the assays in ambulatory patients. Therefore, we evaluated the SARS-CoV-2-IgG response in 51 SASR-CoV-2-PCR-confirmed outpatients with five commercial immunoassays. The sensitivity in serum samples, collected at a median of 24 days after onset of symptoms, detected by the Anti-SARS-CoV-2-ELISA IgG (Euroimmun), EDI? Novel Coronavirus COVID-19 IgG ELISA (Epitope Diagnostics), Liaison? SARS-CoV-2 S1/S2 IgG (Diasorin), SARS-CoV-2 IgG on the Architect? i2000 (Abbott), and Elecsys? Anti-SARS-CoV-2 (IgM/IgA/IgG) on the cobas? e801 (Roche) was 84.3%, 78.4%, 74.5%, 86.3%, and 88.2%, respectively. The sensitivity in serum samples, collected >20 days after onset of symptoms, varied between 75.0% and 90.0%, and in samples, collected at least 28 days after onset of symptoms, did not increase, except in the Anti-SARS-CoV-2-ELISA IgG by Euroimmun (90.0%). There was not an obvious association between the type of the antigen (N versus S protein) and the overall sensitivity of the assays. Our results show significant individual differences of the IgG response against SARS-CoV-2, additionally confirmed in three patients with follow-up serum samples and seven asymptomatic but PCR-positive contact persons. In conclusion, our study shows that commercially available immunoassays detect SARS-CoV-2-IgG or total antibodies in outpatients with a satisfying sensitivity, but lower than that reported for hospitalized patients. In asymptomatic persons the SARS-CoV-2-IgG response may even be absent in a relevant percentage of persons.
機(jī)譯：已經(jīng)開發(fā)了可商購的免疫測定，用于對SARS-COV-2的抗體進(jìn)行敏感和特異性檢測。雖然在住院的Covid-19患者中報(bào)告了高敏感性，但關(guān)于動態(tài)患者中的測定的性能很少。因此，我們在51例SASR-COV-2-2-PCR確認(rèn)的外分門診患者中評估了SARS-COV-2-IgG響應(yīng)，具有五種商業(yè)免疫測定。血清樣品中的敏感性，在癥狀發(fā)生后24天的中位數(shù)，由抗SARS-COV-2-ELISA IGG（Euroimmun），EDI?新型冠狀病毒Covid-19 IgG Elisa（表位診斷），聯(lián)絡(luò)?SARS-COV-2 S1 / S2 IgG（DiaSorin），SARS-COV-2 IGG在ArterCl?I2000（Abbott）和COBAS?上的Elecsys?Act-SARS-COV-2（IGM / IGA / IGG）上E801（Roche）分別為84.3％，78.4％，74.5％，86.3％和88.2％。血清樣品中的敏感性，癥狀發(fā)生后20天，在75.0％和90.0％之間變化，在樣品中，至少在癥狀發(fā)作后至少28天收集，除非抗SARS-COV - 2-Elisa Igg由Euroimmun（90.0％）?？乖∟與S蛋白質(zhì)）的類型與測定的整體敏感性之間沒有明顯的關(guān)聯(lián)。我們的結(jié)果表明，對SARS-COV-2的IgG反應(yīng)的顯著性差異，另外在三個隨訪血清樣本和七個無癥狀但PCR陽性接觸人的患者中確認(rèn)。總之，我們的研究表明，商業(yè)上可獲得的免疫測定檢測SARS-COV-2-IgG或全抗體，以滿足敏感性，但低于住院患者的患者。在無癥狀的人中，SARS-COV-2-IgG反應(yīng)甚至可以在相關(guān)百分比中缺席。

著錄項(xiàng)

相似文獻(xiàn)

  • 外文文獻(xiàn)
  • 中文文獻(xiàn)
  • 專利
代理獲取

客服郵箱：kefu@zhangqiaokeyan.com

京公網(wǎng)安備：11010802029741號 ICP備案號：京ICP備15016152號-6 六維聯(lián)合信息科技 (北京) 有限公司?版權(quán)所有

  • 客服微信

  • 服務(wù)號